US FDA user-fee reauthorization legislation is proceeding through Congress, most recently with a May 11 markup in the Senate Health, Education, Labor and Pensions Committee, and lawmakers want a bill passed by July.
But it has already been almost nine months since FDA and industry trade groups completed negotiations on the underlying agreement that forms the basis of the reauthorization legislation. (Also see "Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations" - Medtech Insight, 23 August, 2016
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?